Back to All Ideas
Energy·10:16 AM ET · Tuesday, June 16, 2026·3 min read

Bank of America Upgrades Exxon Mobil (NYSE: XOM) to Buy, Sets $154 Price Target

Alpha Stocks Insight Staff

Independent stock news and analysis covering NASDAQ and NYSE markets.

Share

BofA lifted XOM to Buy from Neutral with a $154 target, citing an attractive valuation after the stock's pullback from its 52-week highs.

Bank of America upgraded Exxon Mobil Corporation (NYSE: XOM) to Buy from Neutral and set a price target of $154, arguing that a pullback from the stock's recent highs has created an attractive entry point. The call came as XOM traded at $141.13 on Tuesday, June 16, 2026, gaining 0.15% on the session, and sits well below its 52-week high of $176.41.

What Changed

  • Rating: Bank of America raised its recommendation on XOM to Buy from Neutral.
  • Price target: B of A Securities set a new price target of $154, implying upside of roughly 9% from Tuesday's close of $141.13.
  • Rationale: BofA cited the stock's pullback from its highs as having created an attractive valuation, a case the bank argued holds regardless of whether a U.S.-Iran peace agreement materializes.
  • 52-week context: XOM's current price of $141.13 represents a significant discount to its 52-week high of $176.41 and a premium to its 52-week low of $105.53.

Why It Matters

Bank of America's upgrade frames XOM as a valuation opportunity rather than a macro bet. By explicitly noting the thesis holds with or without a peace deal between the U.S. and Iran, the bank separated the investment case from near-term geopolitical uncertainty surrounding global oil flows, including developments around the Strait of Hormuz.

For a company of Exxon Mobil's scale as one of the world's largest integrated fuels, lubricants, and chemical companies, a Buy rating from a major institutional firm carries weight with large-cap equity allocators. The upgrade adds to a backdrop where the broader analyst community has maintained a constructive stance on the stock.

Wall Street View

Bank of America's upgrade to Buy adds to a consensus that leans positive on XOM. As of June 1, 2026, the aggregated Wall Street consensus stood at 6 Strong Buy, 10 Buy, 14 Hold, and 1 Sell recommendations, a distribution unchanged from the prior month's tally of 6 Strong Buy and 10 Buy. BofA's move reinforces the bullish end of the spectrum with a concrete $154 price target attached. The stock's forward price-to-earnings ratio of 13.3x is the type of valuation gap BofA appears to be flagging as the core of its thesis.

Investor Takeaway

Bank of America's $154 price target on XOM represents a specific, near-term upside case anchored in valuation rather than commodity-price speculation. With the stock at $141.13 and the broader analyst community holding a net-positive consensus, the upgrade adds institutional weight to the argument that recent price weakness has opened a re-entry window. Investors will be watching whether XOM's next operational update supports the valuation reset BofA is counting on.

XOMExxon Mobilanalyst upgradeBank of America

Found this useful? Share it:

Share

Related Articles

Important Legal Disclaimer

This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.

Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.

Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.